Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer ; volume:17 ; number:3 ; day:5 ; month:5 ; year:2022 ; pages:381 ; date:5.2022
Targeted oncology ; 17, Heft 3 (5.5.2022), 381, 5.2022
- Urheber
-
Scott, Lesley J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-022-00885-y
- URN
-
urn:nbn:de:101:1-2022081423181431302516
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Scott, Lesley J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer